LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...

AstraZeneca said it is in China ‘for the long haul’ and outlined billions of pounds of investment in the US – but a new ...

AstraZeneca has put a £450m investment in Britain under review in a stand-off with ministers over state aid. The drugs giant ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

AstraZeneca’s new U.S. spending also leaves in doubt the pharmaceutical company’s plans to invest in a vaccine site in ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

AstraZeneca's £450 million investment plan for vaccine R&D in the UK is under review as discussions on governmental ...

AstraZeneca, the London-listed pharmaceutical company, has put its planned £650 million investment in UK vaccine research and ...

Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...

AstraZeneca is set to report its third-quarter 2024 earnings Tuesday morning. The company's Q2 performance suggests strong ...

The other group at the highest risk when it comes to RSV is children under age five, and specifically infants—especially ...